APA

Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Rekhtman G., Masliak Z., Robak P., Esseltine D., Feng H., Deraedt W., van de Velde H. & Arnulf B. (20151022). Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. : Haematologica.

Chicago

Moreau Philippe, Pylypenko Halyna, Grosicki Sebastian, Karamanesht Ievgenii, Leleu Xavier, Rekhtman Grigoriy, Masliak Zvenyslava, Robak Pawel, Esseltine Dixie-Lee, Feng Huaibao, Deraedt William, van de Velde Helgi and Arnulf Bertrand. 20151022. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. : Haematologica.

Harvard

Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Rekhtman G., Masliak Z., Robak P., Esseltine D., Feng H., Deraedt W., van de Velde H. and Arnulf B. (20151022). Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. : Haematologica.

MLA

Moreau Philippe, Pylypenko Halyna, Grosicki Sebastian, Karamanesht Ievgenii, Leleu Xavier, Rekhtman Grigoriy, Masliak Zvenyslava, Robak Pawel, Esseltine Dixie-Lee, Feng Huaibao, Deraedt William, van de Velde Helgi and Arnulf Bertrand. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. : Haematologica. 20151022.